Originally published byEU-Startups
Telum Therapeutics, a Spanish BioTech company, today announced the successful completion of an €18 million Series A financing to advance its lead programme targeting hospital-acquired (HABP) and ventilator-associated bacterial pneumonia (VABP). AMR Action Fund led the financing round, with participation from new investor Inveready and continued support from existing investors Invivo Partners, CDTI with its […]
The post Telum Therapeutics raises €18 million to advance treatments for hospital-acquired infections appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
Finland’s CurifyLabs raises €12 million to expand 3D printing-based medicine compounding
22h ago
NASA says it will isolate volunteers from the outside world for a year
3d ago
NetNut cracked as Google and FBI target 2 million-device botnet
3d ago
Google DeepMind and A24 announce first-of-its-kind research partnership
3d ago
London’s geoSurge raises €10 million to help brands understand AI-generated outputs
3d ago